<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26442/2075-082X_14.3.21-27</article-id><article-id custom-type="elpub" pub-id-type="custom">systhiper-513</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Поиск ранних маркеров кардиотоксичности противоопухолевого лечения у больных раком молочной железы в зависимости от уровня артериального давления</article-title><trans-title-group xml:lang="en"><trans-title>Markers of early cardiotoxicity in patients with breast cancer undergoing chemotherapy depending on blood pressure level</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авалян</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Avalyan</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">ani_avalian@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кириллова</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirillova</surname><given-names>M. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шитов</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shitov</surname><given-names>V. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ощепкова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Oshchepkova</surname><given-names>Ye. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саидова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Saidova</surname><given-names>M. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стенина</surname><given-names>М. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Stenina</surname><given-names>M. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>I. Ye.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ кардиологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.L.Myasnikov Institute of Clinical Cardiology National Research Medical Center of Cardiology of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N.Blokhin National Research Medical Center of Oncology of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>14</volume><issue>3</issue><fpage>21</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Авалян А.А., Кириллова М.Ю., Шитов В.Н., Ощепкова Е.В., Саидова М.А., Стенина М.Б., Чазова И.Е., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Авалян А.А., Кириллова М.Ю., Шитов В.Н., Ощепкова Е.В., Саидова М.А., Стенина М.Б., Чазова И.Е.</copyright-holder><copyright-holder xml:lang="en">Avalyan A.A., Kirillova M.Y., Shitov V.N., Oshchepkova Y.V., Saidova M.A., Stenina M.B., Chazova I.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/513">https://www.syst-hypertension.ru/jour/article/view/513</self-uri><abstract><p>Цель исследования - изучить возможности метода недопплеровского изображения миокарда (Speckle Tracking Imaging) в двумерном режиме (2D Strain) для раннего выявления кардиотоксичности у больных раком молочной железы (РМЖ) в сочетании с артериальной гипертонией (АГ) на фоне проведения антрациклинсодержащей химиотерапии. Материалы и методы. В исследование были включены 70 больных тройным негативным РМЖ (средний возраст 48,6±13,3 года), получавших химиотерапию с включением антрациклинов, таксанов и производных платины (8 курсов). Больным выполнялось ультразвуковое исследование сердца, включая метод недопплеровского изображения миокарда (Speckle Tracking Imaging) в двумерном режиме (2D Strain) до и после 8 курсов химиотерапии. Для оценки глобальной систолической функции ЛЖ определялись фракция выброса левого желудочка (ФВ ЛЖ) (по методу Simpson’s Biplane) и показатель глобального продольного стрейна (глобальная продольная деформация левого желудочка - global longitudinal strain, GLS, по данным метода недопплеровского изображения миокарда в двумерном режиме). Больные были разделены на 2 группы: 1-я группа (n=18) - больные с анамнезом АГ и 2-я группа (n=52) - без анамнеза АГ. Результаты. Значения показателя GLS до начала курсов химиотерапии в 1-й группе (с АГ) были ниже нормальных значений (-19,1±2,8% vs -22,1±1,8%; p&lt;0,05) и ниже, чем во 2-й группе, без АГ (-20,1±2,8%; p&gt;0,05). После 8 курсов химиотерапии наблюдалось снижение показателя GLS как в общей группе (с -20,0±2,8 до -18,5±2,9%; p&lt;0,05), так и в 1 и 2-й группах: в 1-й группе выявлено снижение с -19,1±2,8 до -16,4±3,8% (р&lt;0,05); во 2-й группе с -20,1±2,8 до -19,2±2,4% (p&lt;0,05). Значения показателя GLS снизились более чем на 15% у 12 (17%) женщин из всех наблюдаемых больных. Несмотря на то, что ФВ ЛЖ снижалась в обеих группах, она находилась в пределах допустимых значений (норма ФВ ЛЖ&gt;55%). Заключение. GLS по данным метода недопплеровского изображения миокарда (Speckle Tracking Imaging) в двумерном режиме (2D Strain), вероятно, является одним из наиболее ранних маркеров кардиотоксичности, индуцированной химиотерапией, по сравнению с показателем ФВ ЛЖ.</p></abstract><trans-abstract xml:lang="en"><p>Objective. To study the possibility of the 2D Speckle Tracking Imaging in early detection of cardiotoxicity in patients with triple negative breast cancer and arterial hypertension (AH) during anthracycline-containing chemotherapy. Materials and methods. 70 women (mean age 48.6±13.3 years) with triple negative breast cancer were enrolled. All patients underwent chemotherapy, including anthracycline, taxan, platinum-based agent. Echocardiography, including 2D Speckle Tracking Imaging, was performed on Vivid-E 9 ultrasound machine before and after 8 weeks of chemotherapy. Left ventricular ejection fraction (LVEF) (the biplane Simpson`s method) and global longitudinal strain (GLS) (mean normal GLS of -22.1±1.8 for women) were analysed. Patients were divided into two groups: group 1 - with AH (n=18) and group 2 - with normal blood pressure (n=52). Results. Before chemotherapy in group 1 GLS was lower than normal value (-19.1±2.8% vs -22.1±1.8%; p&lt;0.05) and lower than in the group 2 (-19.1±2.8% vs -20.0±2.8%; p&gt;0.05). After chemotherapy in all patients GLS decrease was observed from -20.0±2.8% to -18.5±2.9% (p&lt;0.05) and in group 1 from -19.1±2.8% to -16.4±3.8% (р&lt;0.05), group 2 from -20.0±2.8% to -19.2±2.4% (p&lt;0.05). However LVEF remained within normal values. The values of GLS decreased by more than 15% in 12 (17%) of all the patients. Conclusions. Apparently, GLS is the one of most sensitive early marker of chemotherapy - induced cardiotoxicity compared with the LVEF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>кардиоонкология</kwd><kwd>артериальная гипертония</kwd><kwd>кардиотоксичность</kwd><kwd>глобальный продольный стрейн левого желудочка</kwd><kwd>химиотерапия</kwd><kwd>рак молочной железы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardio-oncology</kwd><kwd>arterial hypertension</kwd><kwd>cardiotoxicity</kwd><kwd>global longitudinal strain of the left ventricle</kwd><kwd>chemotherapy</kwd><kwd>breast cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Brana I, Tabernero J. Cardiotoxicity. Ann Oncol 2010; 21: 173-9.</mixed-citation><mixed-citation xml:lang="en">Brana I, Tabernero J. Cardiotoxicity. Ann Oncol 2010; 21: 173-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gillespie H.S, McGann C.J, Wilson B.D. Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardiol Rev 2011; 7: 234-44.</mixed-citation><mixed-citation xml:lang="en">Gillespie H.S, McGann C.J, Wilson B.D. Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardiol Rev 2011; 7: 234-44.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen B.V. Cardiotoxic consequences of anthracyline-containing therapy in patients with breast cancer. Semin Oncol 2006; 33: 15-21.</mixed-citation><mixed-citation xml:lang="en">Jensen B.V. Cardiotoxic consequences of anthracyline-containing therapy in patients with breast cancer. Semin Oncol 2006; 33: 15-21.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Doyle J.J, Neugut A.I, Jacobson J.S. et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23: 8597-605.</mixed-citation><mixed-citation xml:lang="en">Doyle J.J, Neugut A.I, Jacobson J.S. et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23: 8597-605.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hooning M.J, Botma A, Aleman B.M. et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365-75.</mixed-citation><mixed-citation xml:lang="en">Hooning M.J, Botma A, Aleman B.M. et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365-75.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Корнеева О.Н., Драпкина О.М., Козлова Е.В. и др. Кардиомиопатия, индуцированная полихимиотерапией, у больных раком молочной железы. Клиницист. 2011; 3: 109-11.</mixed-citation><mixed-citation xml:lang="en">Корнеева О.Н., Драпкина О.М., Козлова Е.В. и др. Кардиомиопатия, индуцированная полихимиотерапией, у больных раком молочной железы. Клиницист. 2011; 3: 109-11.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Шуйкова К.В., Емелина Е.И., Гендлин Г.Е. и др. Кардиотоксичность современных химиотерапевтических препаратов. АтмосферA. Новости кардиологии. 2012; 3: 9-19</mixed-citation><mixed-citation xml:lang="en">Шуйкова К.В., Емелина Е.И., Гендлин Г.Е. и др. Кардиотоксичность современных химиотерапевтических препаратов. АтмосферA. Новости кардиологии. 2012; 3: 9-19</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC 2010; 55 (3): 213-20.</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC 2010; 55 (3): 213-20.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю. и др. Риск развития артериальной гипертонии у пациентов с онкологическими заболеваниями на фоне противоопухолевого лечения. Consilium Medicum. 2016; 18 (1): 16-20</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю. и др. Риск развития артериальной гипертонии у пациентов с онкологическими заболеваниями на фоне противоопухолевого лечения. Consilium Medicum. 2016; 18 (1): 16-20</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю. и др. Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем. Системные гипертензии. 2015; 12 (2): 6-7</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю. и др. Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем. Системные гипертензии. 2015; 12 (2): 6-7</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sadurska E. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors. Pediatr Cardiol 2015; 36: 1112-9.</mixed-citation><mixed-citation xml:lang="en">Sadurska E. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors. Pediatr Cardiol 2015; 36: 1112-9.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">ВОЗ. URL: http://www.who.int/ru/ / VOZ. URL: http://www.who.int/ru/ [in Russian]</mixed-citation><mixed-citation xml:lang="en">ВОЗ. URL: http://www.who.int/ru/ / VOZ. URL: http://www.who.int/ru/ [in Russian]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Piccirillo J.F, Tierney R.M, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291 (20): 2441-7.</mixed-citation><mixed-citation xml:lang="en">Piccirillo J.F, Tierney R.M, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291 (20): 2441-7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шарипова Г.Х., Саидова М.А., Жернакова Ю.В., Чазова И.Е. Влияние метаболического синдрома у больных артериальной гипертонией. Альманах клинической медицины. 2015; 1 (Спецвып.): 102-10</mixed-citation><mixed-citation xml:lang="en">Шарипова Г.Х., Саидова М.А., Жернакова Ю.В., Чазова И.Е. Влияние метаболического синдрома у больных артериальной гипертонией. Альманах клинической медицины. 2015; 1 (Спецвып.): 102-10</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Erika Matos , Borut Jug, Rok Blagus et al. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients. Arq Bras Cardiol 2016; 107 (1): 40-47.</mixed-citation><mixed-citation xml:lang="en">Erika Matos , Borut Jug, Rok Blagus et al. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients. Arq Bras Cardiol 2016; 107 (1): 40-47.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Robin K. Kuriakose, Rakesh C. Kukreja, and Lei Xi Potential. Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs. Oxid Med Cell Longev 2016; Article ID 8139861; 9.</mixed-citation><mixed-citation xml:lang="en">Robin K. Kuriakose, Rakesh C. Kukreja, and Lei Xi Potential. Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs. Oxid Med Cell Longev 2016; Article ID 8139861; 9.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (Suppl. 5): 277-82.</mixed-citation><mixed-citation xml:lang="en">Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (Suppl. 5): 277-82.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Seidman A, Hudis C, Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.</mixed-citation><mixed-citation xml:lang="en">Seidman A, Hudis C, Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Daher I.N, Kim C, Saleh R.R. et al. Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients. Echocardiography 2011; 28: 1061-7.</mixed-citation><mixed-citation xml:lang="en">Daher I.N, Kim C, Saleh R.R. et al. Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients. Echocardiography 2011; 28: 1061-7.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Plana J.C, Galderisi M, Barac A et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911-39.</mixed-citation><mixed-citation xml:lang="en">Plana J.C, Galderisi M, Barac A et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911-39.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mondillo S, Galderisi M, Mele D. et al. Speckle-Tracking Echocardiography: A New Technique for Assessing Myocardial Function. J Ultrasound Med 2011; 30: 71-8.</mixed-citation><mixed-citation xml:lang="en">Mondillo S, Galderisi M, Mele D. et al. Speckle-Tracking Echocardiography: A New Technique for Assessing Myocardial Function. J Ultrasound Med 2011; 30: 71-8.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zamorano J.L, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper on cancer treatment and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; August 26: 1-34. doi:10.1093/eurheartj/ehw211</mixed-citation><mixed-citation xml:lang="en">Zamorano J.L, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper on cancer treatment and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; August 26: 1-34. doi:10.1093/eurheartj/ehw211</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lenihan D.J, Kowey P.R. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 2013; 18: 900-8.</mixed-citation><mixed-citation xml:lang="en">Lenihan D.J, Kowey P.R. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 2013; 18: 900-8.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Васюк Ю.А., Школьник Е.Л. и др. Антрациклиновая кардиотоксичность: перспективы использования ивабрадина. Кардиосоматика. 2012; 3 (4): 65-9.</mixed-citation><mixed-citation xml:lang="en">Васюк Ю.А., Школьник Е.Л. и др. Антрациклиновая кардиотоксичность: перспективы использования ивабрадина. Кардиосоматика. 2012; 3 (4): 65-9.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J 2011; 38 (3): 263-5.</mixed-citation><mixed-citation xml:lang="en">Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J 2011; 38 (3): 263-5.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Crawford S.C. Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer: Are There Implications for Blood Pressure Management in Patients Receiving Chemotherapy? J Clin Oncol 2006; 24 (15): 2399-400.</mixed-citation><mixed-citation xml:lang="en">Crawford S.C. Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer: Are There Implications for Blood Pressure Management in Patients Receiving Chemotherapy? J Clin Oncol 2006; 24 (15): 2399-400.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Radwan H, Hussein E. Value of global longitudinal strain by two dimensional speckle tracking echocardiography in predicting coronary artery disease severity. Egypt Heart J 2017; 69: 95-101.</mixed-citation><mixed-citation xml:lang="en">Radwan H, Hussein E. Value of global longitudinal strain by two dimensional speckle tracking echocardiography in predicting coronary artery disease severity. Egypt Heart J 2017; 69: 95-101.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Stoodley P.W, Richards D.A, Boyd A. et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging 2013; 14 (3): 228-34.</mixed-citation><mixed-citation xml:lang="en">Stoodley P.W, Richards D.A, Boyd A. et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging 2013; 14 (3): 228-34.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Portugal G, Moura Branco L, Galrinho A. et al. Global and regional patterns of longitudinal strain in screening for chemotherapy-induced cardiotoxicity. Rev Port Cardiol 2017; 36 (1): 9-15.</mixed-citation><mixed-citation xml:lang="en">Portugal G, Moura Branco L, Galrinho A. et al. Global and regional patterns of longitudinal strain in screening for chemotherapy-induced cardiotoxicity. Rev Port Cardiol 2017; 36 (1): 9-15.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Boyd A, Stoodley P, Richards D. et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS One 2017; 12 (4): e0175544; 15.</mixed-citation><mixed-citation xml:lang="en">Boyd A, Stoodley P, Richards D. et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS One 2017; 12 (4): e0175544; 15.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Fraeman K.H, Nordstrom B.L, Luo W. et al. Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study. Int J Hypertens 2013. Article ID 379252; 10.</mixed-citation><mixed-citation xml:lang="en">Fraeman K.H, Nordstrom B.L, Luo W. et al. Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study. Int J Hypertens 2013. Article ID 379252; 10.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
